Glyceryl: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Glyceryl

Active ingredient

GB MHRA

Drug class: -
Availability: See label
Markets covered: 1
Products on record: 5

Overview

Glyceryl is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	5	May 15, 2026

GBUnited Kingdom· MHRA

5 products

Uses

GBOfficial regulatory label· revised May 15, 2026[1]

As a short-acting vasodilator in the • Relief of angina pectoris • Prophylaxis of angina pectoris • Relief of acute spontaneous coronary artery spasm

How to take

Sources & citations

[1]MHRA (UK) · PL001426297 · revised May 15, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 15, 2026[1]

System Organ Class Very Common (≥ 1/10) Common (≥ 1/100 < 1/10) Uncommon (≥ 1/1,000 < 1/100) Rare (≥ 1/10,000 < 1/1,000) Very Rare (< 1/10,000) Frequency not known (cannot be estimated from the available data) Blood and lymphatic system disorders Methaemoglobinaemia Psychiatric disorder Restlessness Nervous system disorders Throbbing headache** Vertigo**, Dizziness**, Drowsiness Syncope Cerebral ischaemia Eye disorders Increased ocular pressure Cardiac disorders Tachycardia Enhanced angina, Pectoris symptoms, Bradycardia, Cyanosis Hypoxaemia, palpitations Vascular disorders Orthostatic hypertension*, Facial flushing, Circulatory collapse Gastrointestinal disorders Nausea, Vomiting Heartburn, Halitosis Respiratory, thorasic and mediastinal disorders Impairment of respiration Skin and subcutaneous tissue disorders Allergic skin reactions Exfoliative dermatitis, Drug rash General disorders and administration site complications Asthenia Localised burning sensation, tongue blisters Weakness Investigations Blood pressure decreased* * Particularly upon initiation of therapy and following an increase in dose.
** Headache and dizziness, persisting after relief of angina may be minimised by removing the glyceryl trinitrate tablet before it has completely dissolved. Glyceryl trinitrate-induced hypotension may cause cerebral ischaemia. Large dose of glyceryl trinitrate may cause vomiting, cyanosis, restlessness, methaemoglobinaemia and impairment of respiration.
During treatment with glyceryl trinitrate, temporary hypoxemia may occur due to a relative redistribution of the blood flow in hypoventilated alveolar areas. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 15, 2026[1]

g. acute circulatory shock including hypovolemic shock or cardiogenic shock with inadequate diastolic filling pressures, severe mitral stenosis, pericardial tamponade, constrictive pericarditis, orthostatic dysfunction) because administration of a vasodilator in these patients may worsen clinical status.
Glyceryl trinitrate should be used with caution in patients with severe hypotension (systolic blood pressure below 90 mm Hg) and patients with cardiogenic shock, unless a sufficiently high left ventricular end diastolic pressure is assured by intra-aortal counterpulsation or positive inotropic drugs.
Glyceryl trinitrate should be used with caution in patients with cerebrovascular disease since symptoms may be precipitated by hypotension. Glyceryl trinitrate may worsen hypoxaemia in patients with lung disease or cor pulmonale. Arterial hypotension with bradycardia may occur in patients with myocardial infarction; this is thought to be reflexly mediated.
The use of glyceryl trinitrate could theoretically compromise myocardial blood supply in patients with left ventricular hypertrophy associated with aortic stenosis because of the detrimental effects of tachycardia and decreased aortic diastolic pressure.
Detailed haemodynamic studies in a small number of patients with valvular aortic stenosis with and without concomitant significant coronary artery disease studied in the supine position have not shown adverse effects with sublingual glyceryl trinitrate.
However it seems prudent to be cautious in treating ambulant patients with the combination of angina and moderate to severe valvular aortic stenosis. Caution is necessary in patients with severe hepatic or renal impairment, hypothyroidism, hypoxaemia, hypothermia or a recent history of myocardial infaraction and malnutrition.
2). Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This is not medical advice. Consult a qualified healthcare professional.